Related content

Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers

By Pedersen Rasmus Steen   Damkier Per   Brøsen Kim  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 7, 2006-07 ,pp. : 513-521

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in Healthy CYP2D6 Extensive and Poor Metabolizers: A Randomized, Open-Label, Two-Period, Parallel-Group, Crossover Study

By Nichols Alice I.  

Clinical Drug Investigation, Vol. 31, Iss. 3, 2011-03 ,pp. : 155-167

Adis International

Access to resources Recommend Favorite

Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations

By Uno Tsukasa   Niioka Takenori   Hayakari Makoto   Yasui-Furukori Norio   Sugawara Kazunobu   Tateishi Tomonori  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 2, 2007-02 ,pp. : 143-149

Springer Publishing Company

Access to resources Recommend Favorite

The effect of Shoseiryuto, a traditional Japanese medicine, on cytochrome P450s, N-acetyltransferase 2 and xanthine oxidase, in extensive or intermediate metabolizers of CYP2D6

By Nakao Masashi   Muramoto Yousuke   Hisadome Motoko   Yamano Naoko   Shoji Mami   Fukushima Yumi   Saruwatari Junji   Nakagawa Kazuko  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 4, 2007-04 ,pp. : 345-353

Springer Publishing Company

Access to resources Recommend Favorite

Cytochrome P450 2C19 (CYP2C19) genotype appears to affect the efficacy of omeprazole

By  

Inpharma, Vol. 1, Iss. 1221, 2000-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite